Therapeutic Prospects for Friedreich’s Ataxia
- 1 April 2019
- journal article
- editorial
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 40 (4) , 229-233
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Neurological Disorders and Stroke
- National Institutes of Health (R01NS081366, R21 NS101145, R03 NS099953)
- Friedreich’s Ataxia Research Alliance
- Muscular Dystrophy Association (MDA418838)
- National Ataxia Foundation
- American Academy of Neurology
- CRISPR Therapeutics
This publication has 19 references indexed in Scilit:
- Rapid and Complete Reversal of Sensory Ataxia by Gene Therapy in a Novel Model of Friedreich AtaxiaMolecular Therapy, 2018
- Progress in the treatment of Friedreich ataxiaNeurologia i Neurochirurgia Polska, 2018
- Synthetic transcription elongation factors license transcription across repressive chromatinScience, 2017
- Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAsNucleic Acids Research, 2017
- Emerging therapeutics for the treatment of Friedreich’s ataxiaExpert Opinion on Orphan Drugs, 2017
- Pharmacological therapeutics in Friedreich ataxia: the present stateExpert Review of Neurotherapeutics, 2017
- Activating frataxin expression by repeat-targeted nucleic acidsNature Communications, 2016
- Excision of Expanded GAA Repeats Alleviates the Molecular Phenotype of Friedreich's AtaxiaMolecular Therapy, 2015
- Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxiaNature Medicine, 2014
- Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat ExpansionScience, 1996